Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3236-6
Abstract: The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains an incurable disease with unavoidable… read more here.
Keywords: relapsed refractory; based regimen; pom dex; therapy ... See more keywords
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps8059
Abstract: TPS8059Background: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved in the United States and Europe for use as a monotherapy and in combination with bortezomib/dexamethasone or le... read more here.
Keywords: without daratumumab; dex without; dara; pomalidomide dexamethasone ... See more keywords